Month: March 2023

─ APTIVATE Expansion Trial of Tuspetinib as Single Agent in Relapsed/Refractory AML Patients is Up and Running; Initiated Enrollment of Combination Treatment Arm with Venetoclax ─ ─ RAS Mutated AML Clinically Sensitive to Tuspetinib ─ ─ Continuous Dosing of G3 Formulation of Luxeptinib Ongoing ─ ─ Conference Call and Webcast at 5:00 pm ET Today ─ SAN DIEGO and TORONTO, March 23, 2023 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced financial results for the fourth quarter and year ended December 31, 2022, and provided a corporate update. The net loss for the quarter ended December 31, 2022, was $10.0 million ($0.11 per share) compared...

Significant Sales and Technology Investments Drive $94.3 Million in Total Revenue and Ongoing Client Acquisition Momentum 2022 Fourth Quarter Cost-Optimization Initiatives Provide Significant Adjusted EBITDA Benefit and Position Company Closer to Reaching Profitability TUSTIN, Calif., March 23, 2023 (GLOBE NEWSWIRE) — Nogin (Nasdaq: NOGN) (“Nogin” or the “Company”), a leading provider of innovative Commerce-as-a-Service (“CaaS”) technology, today reported its financial results for the fourth quarter and full year ended December 31, 2022. Management Commentary“In a year largely defined by global market uncertainty, 2022 was a transformational year for our organization,” said Nogin CEO Jon Huberman. “Our technology is at the heart of what we do, and our efforts last year to develop our revolutionary Intelligent Commerce Platform...

NEW YORK, March 23, 2023 (GLOBE NEWSWIRE) — TMC the metals company Inc. (Nasdaq: TMC) (“TMC” or “the Company”), an explorer of lower-impact battery metals from seafloor polymetallic nodules, today provided a corporate update and financial results for the fourth quarter ending December 31, 2022. Q4 2022 and FY 2022 Financial HighlightsNet loss of $109.6 million and loss per share of $0.41 for the quarter ended December 31, 2022. Following the successful conclusion of the integrated pilot nodule collection system trial in November 2022, we recorded $69.9 million related to the fair value on grant date ($7 per DeepGreen share in March 2021) of the 10 million Allseas warrants which became exercisable and $8.7 million related to 10.85 million shares issued to Allseas as completion payment, both of which were announced last quarter For...

Fourth Quarter 2022 Revenue and Full-Year 2022 Revenue Up 137% and 66% Year-Over-Year Respectively SAN DIEGO, March 23, 2023 (GLOBE NEWSWIRE) — KULR Technology Group, Inc. (NYSE American: KULR) (the “Company” or “KULR”), a leading energy management platform company accelerating the global transition to a sustainable electrification economy, today announced its financial results for the fourth quarter and full-year 2022. “Often upfront costs are required to secure exponential future growth – over the course of 2022, KULR was able to maintain gross margins while scaling revenues and adding significant resources to both R&D and buildout of the Company’s technology roadmap,” said KULR CEO Michael Mo. “We continue to capitalize and expand our organization across all facets, as we stated we would do...

INCLINE VILLAGE, Nev., March 23, 2023 (GLOBE NEWSWIRE) — Vintage Wine Estates, Inc. (Nasdaq: VWE and VWEWW) (“VWE” or the “Company”), one of the top wine producers in the U.S. with an industry leading direct-to-consumer platform, today announced that it requires more time to complete processes needed to close its second quarter of fiscal 2023. The Company now expects to file its amended first quarter 2023 10-Q and report its second quarter fiscal 2023 results as soon as practical, but no later than April 30, 2023. The Company had reported on February 8, 2023, that it intends to amend and file its first quarter 2023 10-Q as soon as practical. Investors should no longer rely upon the Company’s previously released financial statements for the first quarter of fiscal 2023. Similarly, related press releases, earnings releases, and investor...

Topline sales gained momentum post-Black Friday, improving sequentially through the fourth quarter including positive total comparable sales in January 2023 Fiscal 2023 year-end inventories down 11% compared to last year with a clearance position less than 5% Cost headwinds are becoming tailwinds through on-going progress of Focus, Simplify and Grow initiative New credit facility agreement strengthens balance sheet for fiscal year 2024HUDSON, Ohio, March 23, 2023 (GLOBE NEWSWIRE) — JOANN Inc. (NASDAQ: JOAN) (“JOANN”), the nation’s category leader in fabric and sewing with one of the largest assortments of arts and crafts products, today reported results for its fourth quarter and full year ended January 28, 2023. JOANN’s President and Chief Executive Officer Wade Miquelon commented, “In fiscal year 2023, we navigated a challenging...

Full-year sales increased 24% to $1.41 billion 2022 operating margin increased 100 basis points to 15.5%, or 130 basis points to 16.6% on an adjusted basis GAAP EPS increased 31% to $10.19 and adjusted EPS increased 36% to $10.88 Initiates fiscal 2023 guidance of revenues of $1.62 billion to $1.66 billion, GAAP EPS of $10.86 to $11.26 and adjusted EPS of $11.50 to $11.90ATLANTA , March 23, 2023 (GLOBE NEWSWIRE) — Oxford Industries, Inc. (NYSE:OXM) today announced financial results for its fourth quarter and full fiscal year 2022 ended January 28, 2023. Consolidated net sales for the full fiscal 2022 year increased 24% to $1.41 billion compared to $1.14 billion in fiscal 2021. Earnings per share (EPS) on a GAAP basis increased 31% to $10.19 compared to $7.78 in fiscal 2021. On an adjusted basis, EPS increased 36% to $10.88 compared...

– Cleared dose-limiting toxicity (DLT) observation period with more frequent, dose-intensive regimen of CAB-AXL BA3011; anticipated leiomyosarcoma (LMS) cohort readout in 2H23 – Initiated the potentially registrational Phase 2, part 2 BA3011 Undifferentiated Pleomorphic Sarcoma (UPS) study in 1H23 including more frequent, dose-intensive regimens – On track for submitting a meeting request to the Food & Drug Administration (FDA) for the potentially registrational BA3011 Phase 2, part 2 non-small cell lung cancer (NSCLC) study in 1H23; anticipate both FDA feedback and initiation of Phase 2, part 2 in 2H23 – Achieved First Patient In (FPI) for CAB-ROR2 BA3021 Phase 2 squamous cell carcinoma of the head & neck (SCCHN) study – Enrolling BA3021 Phase 2 NSCLC study including more frequent, dose-intensive...

On track to complete enrollment in Phase 2/3 LIFT-AD trial of fosgonimeton for mild-to-moderate Alzheimer’s disease in mid-2023 with topline data in early 2024 Continuing to advance development of ATH-1105 as a potential clinical candidate for amyotrophic lateral sclerosis Strong balance sheet to support innovative clinical development pipeline in neurodegenerative diseases through key inflection points BOTHELL, Wash., March 23, 2023 (GLOBE NEWSWIRE) — Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the company’s financial results for the year ended December 31, 2022, and reviewed recent pipeline and business updates. “The progress we made throughout 2022 and in recent months continues...

4Q2022 Total Revenues of $50 Million, a 90% Y-o-Y Increase 4Q2022 Gross Profit of $14 Million, an $11 Million Y-o-Y Increase FY 2023 Total Revenue Expected to Exceed $210 Million First-Time Positive EBITDA Expected No Later than Second Half of 2023 Conference Call Scheduled for Today at 4:30 p.m. ET RAMSEY, N.J. and BOCA RATON, Fla., March 23, 2023 (GLOBE NEWSWIRE) — ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics, today announced its fourth quarter and full year 2022 financial results and provided a business update. “We achieved year-over-year revenue growth of 90% during 2022, advancing ADMA’s position as the fastest growing provider of Immunoglobulin (IG) in the U.S. market....